Novel Prophylactic HIV Vaccines Based on rAAV Vectors

基于 rAAV 载体的新型预防性 HIV 疫苗

• 批准号: 7113913
• 负责人: Philip R Johnson
• 金额: $ 56.95万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2006-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7113913
• 关键词: AIDS vaccines; adeno associated virus group; transfection /expression vector; vaccine development; vector vaccine

DESCRIPTION (provided by applicant): The overall goal of this HIVRAD Program is to develop a second generation HIV-1 vaccine based on recombinant adeno-associated virus (rAAV) vectors. The proposed research in this application builds on our experience with a first generation rAAV/HIV vaccine that is now being tested in Phase I human trials. Although the first generation vaccine is a promising candidate, we believe that substantial room for improvement remains. Based on our preliminary data, we have developed a series of hypothesis driven experiments to achieve this goal. We will enhance antigen-specific T cell responses to the vaccine by (i) significantly augmenting vaccine gene delivery and (ii) directly engaging and modifying host immune responses.

描述（由申请人提供）：